TACR3
Basic information
Region (hg38): 4:103586031-103719985
Links
Phenotypes
GenCC
Source:
- hypogonadotropic hypogonadism 7 with or without anosmia (Strong), mode of inheritance: AR
- Kallmann syndrome (Supportive), mode of inheritance: AD
- hypogonadotropic hypogonadism (Supportive), mode of inheritance: AD
- hypogonadotropic hypogonadism 11 with or without anosmia (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hypogonadotropic hypogonadism | AR | Endocrine | In Hypogonadotropic hypogonadism, surveillance in adolescence related to sexual maturation is indicated, as is monitoring of bone mineral density in order to allow early detection and treatment of disease; In order to induce and maintain secondary sex characteristics, gradually increasing doses of gonadal steroids (females: estrogen/progestin; males: testosterone/hCG) can be beneficial; Related to fertility, endocrinologic therapy (females: recombinant hCG or pulsatile GnRH therapy; males: hCG/HMG/recombinant FSH or pulsatile GnRH therapy) may be effective, though IVF may be required | Endocrine | 19079066; 20301509 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
- Hypogonadotropic hypogonadism (1 variants)
- Hypogonadotropic hypogonadism 11 with or without anosmia (1 variants)
- See cases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TACR3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 17 | 24 | ||||
missense | 30 | 35 | ||||
nonsense | 5 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 0 | |||||
non coding | 12 | 15 | 10 | 37 | ||
Total | 4 | 8 | 48 | 35 | 12 |
Highest pathogenic variant AF is 0.000375
Variants in TACR3
This is a list of pathogenic ClinVar variants found in the TACR3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-103589412-A-G | Likely benign (May 10, 2019) | |||
4-103589480-C-G | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 12, 2018) | ||
4-103589504-CAT-C | Isolated GnRH Deficiency | Uncertain significance (Jun 14, 2016) | ||
4-103589539-C-T | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 13, 2018) | ||
4-103589544-C-T | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 12, 2018) | ||
4-103589557-T-C | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 12, 2018) | ||
4-103589588-A-C | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 12, 2018) | ||
4-103589595-A-G | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 12, 2018) | ||
4-103589609-G-A | Hypogonadotropic hypogonadism 11 with or without anosmia | Benign (Jun 26, 2018) | ||
4-103589687-A-G | Inborn genetic diseases | Likely benign (Apr 07, 2022) | ||
4-103589707-T-C | Uncertain significance (May 06, 2022) | |||
4-103589735-C-A | not specified • Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Nov 09, 2023) | ||
4-103589735-C-T | Hypogonadotropic hypogonadism 11 with or without anosmia • TACR3-related disorder | Benign/Likely benign (Dec 27, 2023) | ||
4-103589736-G-A | not specified • Hypogonadotropic hypogonadism 11 with or without anosmia | Benign/Likely benign (May 23, 2023) | ||
4-103589759-G-A | Hypogonadotropic hypogonadism 11 with or without anosmia | Conflicting classifications of pathogenicity (Aug 31, 2023) | ||
4-103589769-A-G | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 12, 2018) | ||
4-103589790-C-T | Hypogonadotropic hypogonadism 11 with or without anosmia | Conflicting classifications of pathogenicity (Apr 13, 2018) | ||
4-103589791-G-A | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Oct 31, 2018) | ||
4-103589791-G-T | Inborn genetic diseases | Uncertain significance (May 07, 2024) | ||
4-103589834-T-A | Hypogonadotropic hypogonadism 11 with or without anosmia • not specified • TACR3-related disorder | Conflicting classifications of pathogenicity (Oct 21, 2024) | ||
4-103589846-C-T | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Oct 11, 2021) | ||
4-103589850-T-A | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 13, 2018) | ||
4-103589855-T-C | Hypogonadotropic hypogonadism 11 with or without anosmia | Conflicting classifications of pathogenicity (Aug 08, 2018) | ||
4-103589874-G-A | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 13, 2018) | ||
4-103589892-C-T | Hypogonadotropic hypogonadism 11 with or without anosmia | Uncertain significance (Jan 13, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TACR3 | protein_coding | protein_coding | ENST00000304883 | 5 | 133786 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.81e-17 | 0.000950 | 125634 | 0 | 114 | 125748 | 0.000453 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.577 | 233 | 259 | 0.899 | 0.0000131 | 3036 |
Missense in Polyphen | 76 | 93.857 | 0.80974 | 1207 | ||
Synonymous | 0.0427 | 98 | 98.5 | 0.995 | 0.00000508 | 949 |
Loss of Function | -0.972 | 23 | 18.5 | 1.24 | 9.57e-7 | 194 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000512 | 0.000510 |
Ashkenazi Jewish | 0.000298 | 0.000298 |
East Asian | 0.000491 | 0.000489 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000723 | 0.000721 |
Middle Eastern | 0.000491 | 0.000489 |
South Asian | 0.000262 | 0.000261 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K > substance P.;
- Disease
- DISEASE: Hypogonadotropic hypogonadism 11 with or without anosmia (HH11) [MIM:614840]: A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic- pituitary axis. In some cases, it is associated with non- reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). {ECO:0000269|PubMed:19079066, ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900}. Note=The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry. The genetics of hypogonadotropic hypogonadism involves various modes of transmission. Oligogenic inheritance has been reported in some patients carrying mutations in TACR3 as well as in other HH-associated genes including FGFR1, SPRY4 and KAL1 (PubMed:23643382). {ECO:0000269|PubMed:23643382}.;
- Pathway
- Calcium signaling pathway - Homo sapiens (human);Neuroactive ligand-receptor interaction - Homo sapiens (human);Peptide GPCRs;Signaling by GPCR;Signal Transduction;Tachykinin receptors bind tachykinins;Peptide ligand-binding receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;G alpha (q) signalling events;GPCR downstream signalling
(Consensus)
Recessive Scores
- pRec
- 0.143
Intolerance Scores
- loftool
- 0.791
- rvis_EVS
- -0.34
- rvis_percentile_EVS
- 30.56
Haploinsufficiency Scores
- pHI
- 0.105
- hipred
- N
- hipred_score
- 0.455
- ghis
- 0.436
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.849
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tacr3
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); growth/size/body region phenotype; reproductive system phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype;
Gene ontology
- Biological process
- G protein-coupled receptor signaling pathway;tachykinin receptor signaling pathway;aging;positive regulation of heart rate;response to estradiol;regulation of dopamine metabolic process;response to cocaine;hyperosmotic salinity response;response to morphine;positive regulation of blood pressure;regulation of feeding behavior;positive regulation of uterine smooth muscle contraction;positive regulation of flagellated sperm motility
- Cellular component
- nucleus;cytoplasm;plasma membrane;integral component of plasma membrane;dendrite membrane;neuronal cell body membrane;sperm midpiece
- Molecular function
- tachykinin receptor activity;protein binding